Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191
Benzinga Newsdesk 21 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $185 to $191.
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $185 to $191.